Table 3 Meta-analysis of MSCs versus traditional regimens as induction therapy
From: Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis
Outcomes | Number of trials | Number of patients | RR/WMD | 95% CI | p value | Heterogeneity p value (%) |
|---|---|---|---|---|---|---|
1-year AR rate | 4 | 197 | 0.77 | 0.41,1.45 | 0.42 | 18 |
1-year graft survival rate | 3 | 160 | 0.99 | 0.93,1.05 | 0.69 | 0 |
1-year infection rate | 4 | 197 | 0.65 | 0.46,0.9 | 0.01 | 3 |
DGF rate | 2 | 145 | 0.54 | 0.21,1.38 | 0.2 | 34 |
Renal graft function postsurgery | ||||||
 1 month | 3 | 155 | -1.56 | −14.2, 11.08 | 0.81 | 72 |
 3 month | 3 | 155 | 0.15 | −5.63,5.93 | 0.96 | 0 |
 6 month | 3 | 155 | −1.95 | −9.87,5.97 | 0.63 | 62 |
 12 month | 4 | 197 | −1.13 | −7.16,4.89 | 0.71 | 0 |